Amoytop Biotech Gets Exclusive Rights For Tengji Biopharma's Liver Drug

MT Newswires Live

2024/09/23

Xiamen Amoytop Biotech (SHA:688278) obtained the exclusive rights for Tengji (Xiamen) Biopharmaceutical Technology's drug, NM6606, a Saturday filing on the Shanghai Stock Exchange said.

Amoytop Biotech will pay a down payment of 10 million yuan, development milestone payments of up to 75 million yuan and sales milestone payments of up to 60 million yuan, as well as royalty fees based on a certain percentage of annual net sales.

The drug is indicated to treat liver fat metabolism and liver fibrosis-related diseases, the Chinese pharmaceutical company said.

Price (RMB): Â¥60.37, Change: Â¥-0.51, Percent Change: -0.84%

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2469159969"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2469159969\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2469159969?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-09-23 13:21","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2469159969","market":"sh","top_or_hot":-1,"title":"Amoytop Biotech Gets Exclusive Rights For Tengji Biopharma's Liver Drug","media":"MT Newswires Live","content":"<html><body><p> Xiamen Amoytop Biotech (SHA:688278) obtained the exclusive rights for Tengji (Xiamen) Biopharmaceutical Technology's drug, NM6606, a Saturday filing on the Shanghai Stock Exchange said.</p><p>Amoytop Biotech will pay a down payment of 10 million yuan, development milestone payments of up to 75 million yuan and sales milestone payments of up to 60 million yuan, as well as royalty fees based on a certain percentage of annual net sales.</p><p>The drug is indicated to treat liver fat metabolism and liver fibrosis-related diseases, the Chinese pharmaceutical company said.</p><p>Price (RMB): Â¥60.37, Change: Â¥-0.51, Percent Change: -0.84%</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Amoytop Biotech Gets Exclusive Rights For Tengji Biopharma's Liver Drug</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAmoytop Biotech Gets Exclusive Rights For Tengji Biopharma's Liver Drug\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2024-09-23 13:21</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Xiamen Amoytop Biotech (SHA:688278) obtained the exclusive rights for Tengji (Xiamen) Biopharmaceutical Technology's drug, NM6606, a Saturday filing on the Shanghai Stock Exchange said.</p><p>Amoytop Biotech will pay a down payment of 10 million yuan, development milestone payments of up to 75 million yuan and sales milestone payments of up to 60 million yuan, as well as royalty fees based on a certain percentage of annual net sales.</p><p>The drug is indicated to treat liver fat metabolism and liver fibrosis-related diseases, the Chinese pharmaceutical company said.</p><p>Price (RMB): Â¥60.37, Change: Â¥-0.51, Percent Change: -0.84%</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"688278","symbol_name":"特宝生物","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2469159969","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2469159969","pubTimestamp":1727068886,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Xiamen Amoytop Biotech  obtained the exclusive rights for Tengji  Biopharmaceutical Technology's drug, NM6606, a Saturday filing on the Shanghai Stock Exchange said.Amoytop Biotech will pay a down payment of 10 million yuan, development milestone payments of up to 75 million yuan and sales milestone payments of up to 60 million yuan, as well as royalty fees based on a certain percentage of annual net sales.The drug is indicated to treat liver fat metabolism and liver fibrosis-related diseases, the Chinese pharmaceutical company said.Price : 60.37, Change: -0.51, Percent Change: -0.84%","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"688278":"特宝生物","BK0239":"医药制造"},"translate_title":"淘拓生物获得腾基生物肝脏药物独家权利","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"688278":0.9},"content_text":"Xiamen Amoytop Biotech (SHA:688278) obtained the exclusive rights for Tengji (Xiamen) Biopharmaceutical Technology's drug, NM6606, a Saturday filing on the Shanghai Stock Exchange said.Amoytop Biotech will pay a down payment of 10 million yuan, development milestone payments of up to 75 million yuan and sales milestone payments of up to 60 million yuan, as well as royalty fees based on a certain percentage of annual net sales.The drug is indicated to treat liver fat metabolism and liver fibrosis-related diseases, the Chinese pharmaceutical company said.Price (RMB): Â¥60.37, Change: Â¥-0.51, Percent Change: -0.84%","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}